Radiotheranostics · Shanghai

上海君康立泰
生物医药科技有限公司
Junacta Theranostics

Junacta Theranostics

专注于诊疗一体化(Theranostics)放射性药物的研发,以靶向 α 核素治疗与分子影像诊断为核心,为肿瘤患者提供“看得见、打得准”的精准治疗方案。 Junacta develops theranostic radiopharmaceuticals — pairing targeted alpha therapy with molecular imaging — to bring precise, visible, and personalized treatment to cancer patients.

Targeted α Emission · Ac-225
01 — Focus

专注领域Our Focus

诊疗一体化:同一个靶向分子,先诊断、后治疗,全程可视。Theranostics: one targeting molecule — image first, treat next, visible all the way.

α-THERAPY

靶向 α 核素治疗Targeted Alpha Therapy

以锕-225(Ac-225)等 α 核素为核心载荷,利用 α 粒子短射程、高线性能量转移的特性,精准杀伤肿瘤细胞,同时最大限度保护正常组织。Harnessing alpha emitters such as Ac-225 — short range, high LET — to eradicate tumor cells with precision while sparing healthy tissue.

IMAGING

分子影像诊断Molecular Imaging

配套诊断核素(如 Ga-68、F-18)标记同一靶向分子,通过 PET/CT 显像筛选获益人群、评估疗效,实现“所见即所治”。Companion imaging (Ga-68, F-18) on the same targeting vector enables patient selection and response monitoring by PET/CT.

DX → TX

诊疗一体化配对Dx–Tx Pairing

诊断与治疗药物共享同一分子骨架,从患者分层到剂量滴定全程数据闭环,提高临床成功率。Diagnostic and therapeutic agents share one molecular scaffold, closing the data loop from stratification to dosimetry.

02 — Platform

技术平台Technology Platform

【待补充:此处填写平台介绍,例如小型化抗体工程平台——更小尺寸带来更快的肿瘤穿透与血液清除,适配短半衰期核素的药代动力学窗口。注意:专利申请递交前请勿公开未保护的技术细节。】 [Placeholder: describe your platform here — e.g., an engineered small-format antibody platform whose rapid tumor penetration and clearance matches the pharmacokinetic window of short-lived radionuclides. Do not disclose unpatented details before filing.]

DISCOVERY

分子发现Discovery

【待补充:筛选/工程化能力一句话】[Placeholder: one line on screening & engineering capability.]

CONJUGATION

核素偶联Conjugation

【待补充:螯合/标记工艺一句话】[Placeholder: one line on chelation & radiolabeling.]

TRANSLATION

转化开发Translation

【待补充:临床前→临床转化能力一句话】[Placeholder: one line on preclinical-to-clinical translation.]

03 — Pipeline

研发管线Pipeline

【以下为占位示例,请按实际情况修改代号、靶点、适应症与阶段】[Sample placeholders — replace codes, targets, indications and stages.]

项目Program 靶点Target 核素Isotope 适应症Indication 阶段Stage
JTX-001【靶点A】Ac-225【实体瘤】
JTX-002【靶点B】Ac-225【实体瘤】
JTX-003【靶点A】Ga-68诊断Diagnostic

阶段:苗头化合物 → 临床前 → IND → I 期 → II 期(示意)Stages: Lead → Preclinical → IND → Phase I → Phase II (illustrative)

04 — Team

核心团队Leadership

【以下为占位卡片,请替换为真实成员】[Placeholder cards — replace with real members.]

M

【姓名】

Founder / CEO

【一句话履历:例如 ××大学博士,曾任 ×× 公司研发总监,主导 × 个放射药项目进入临床】[One-line bio]

S

【姓名】

CSO

【一句话履历】[One-line bio]

A

【顾问姓名】

Scientific Advisor

【一句话履历】[One-line bio]

05 — News

新闻动态News

2026-07

君康立泰官方网站正式上线Junacta launches its official website

【可替换为融资、合作、会议等真实新闻】[Replace with real news: financing, partnerships, conferences.]

06 — Contact

联系我们Contact

商务合作Business Development
加入我们Careers
地址Address
上海市浦东新区张江高科技园区【待补充详细地址】 Zhangjiang Hi-Tech Park, Pudong, Shanghai, China
Website
www.junacta.com